跳至主要内容
临床试验/TCTR20210807005
TCTR20210807005已完成2 期

Probiotic, Lactobacillus rhamnosus GG, in Reducing Gut-derived Uremic Toxins in Non-dialysis Chronic Kidney Disease Patients, A Randomized Controlled Trial

Ratchadapiseksompotch Research Fund0 个研究点目标入组 60 人开始时间: 2021年8月7日最近更新:
适应症

试验速览

阶段
2 期
状态
已完成
发起方
入组人数
60

研究概览

简要总结

actobacillus rhamnosus GG changed the structure of gut microbiome phyla, therefore improved gut dysbiosis, attenuated GDUT production, and reduced inflammatory responses. Probiotics could play a beneficial role in retarding CKD progression in the future.

研究设计

研究类型
Interventional

入排标准

年龄范围
18 Years 至 75 Years(—)
性别
All

入选标准

  • Age > 18 years old
  • Diagnosed CKD stage 3-5 or estimated glomerular filtration rate (eGFR)
  • between 10-60 ml/min/mm2 who did not undergo renal replacement therapy

排除标准

  • Estimated glomerular filtration rate (eGFR ) less than 10 ml/min/mm2
  • History of kidney transplant
  • On immunosuppressive therapy
  • History of Renal replace therapy except RRT from acute kidney failure
  • Pregnancy at date of participation
  • Diagnosed Inflammatory bowel disease or infection at bowel
  • Diagnosed Cancer who has to ongoing Chemotherapy or in stage 4
  • End-stage diseases : Congestive heart failure NYHA 4, End-stage lung diseases, Cirrhosis
  • Child-Pugh B,C, or patient who has Karnofsky performance score less than 40

研究者

发起方
Ratchadapiseksompotch Research Fund

相似试验